NCT01240460View on ClinicalTrials.gov

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
GlioblastomaAstrocytoma, Grade IV
Interventions
DRUG

XL765 (SAR245409)

Supplied as 10-mg and/or 50-mg capsules

DRUG

XL147 (SAR245408)

Supplied as 100-mg, 150-mg and/or 200-mg tablets

Trial Locations (4)

10021

Investigational Site Number 840002, New York

90024

Investigational Site Number 840001, Los Angeles

94143

Investigational Site Number 840003, San Francisco

02115

Investigational Site Number 840004, Boston

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY